ATE381351T1 - Anwendung des herpes simplex virus glykoproteins- d zur unterdrückung von immunantworten - Google Patents
Anwendung des herpes simplex virus glykoproteins- d zur unterdrückung von immunantwortenInfo
- Publication number
- ATE381351T1 ATE381351T1 AT01963746T AT01963746T ATE381351T1 AT E381351 T1 ATE381351 T1 AT E381351T1 AT 01963746 T AT01963746 T AT 01963746T AT 01963746 T AT01963746 T AT 01963746T AT E381351 T1 ATE381351 T1 AT E381351T1
- Authority
- AT
- Austria
- Prior art keywords
- protein
- nucleic acid
- operably linked
- acid encoding
- regulatory elements
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6075—Viral proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22102500P | 2000-07-27 | 2000-07-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE381351T1 true ATE381351T1 (de) | 2008-01-15 |
Family
ID=22826021
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT01963746T ATE381351T1 (de) | 2000-07-27 | 2001-07-27 | Anwendung des herpes simplex virus glykoproteins- d zur unterdrückung von immunantworten |
Country Status (8)
Country | Link |
---|---|
US (1) | US7569218B2 (de) |
EP (1) | EP1305435B1 (de) |
JP (1) | JP2004505113A (de) |
AT (1) | ATE381351T1 (de) |
AU (2) | AU8467201A (de) |
CA (1) | CA2417364A1 (de) |
DE (1) | DE60131975T2 (de) |
WO (1) | WO2002010410A1 (de) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7717271B2 (en) * | 2005-12-07 | 2010-05-18 | General Electric Company | Membrane structure and method of making |
US20070131609A1 (en) * | 2005-12-08 | 2007-06-14 | General Electric Company | Membrane structure and method of making |
US8207854B2 (en) * | 2009-02-09 | 2012-06-26 | Mach 1 Development, Inc. | Shipping container integrity device and system |
JP5771605B2 (ja) | 2009-05-22 | 2015-09-02 | ジェノセア バイオサイエンシーズ, インコーポレイテッド | 単純ヘルペスウイルス2型に対するワクチン:免疫応答を誘発する組成物および方法 |
WO2011112717A1 (en) * | 2010-03-09 | 2011-09-15 | Biomedical Research Models, Inc. | A novel mucosal vaccination approach for herpes simplex virus type-2 |
EP2643014A4 (de) | 2010-11-24 | 2015-11-11 | Genocea Biosciences Inc | Impfstoffe gegen den herpes-simplex-virus vom typ 2: zusammensetzungen und verfahren zur auslösung einer immunreaktion |
EP2782597B1 (de) | 2011-11-23 | 2022-04-13 | Genocea Biosciences, Inc. | Nukleinsäureimpfstoffe gegen den herpes-simplex-virus vom typ 2: zusammensetzungen und verfahren zur auslösung einer immunreaktion |
EP3519427A4 (de) | 2016-09-28 | 2020-03-11 | Genocea Biosciences Inc. | Verfahren und zusammensetzungen zur behandlung von herpes |
CA3209779A1 (en) | 2021-02-01 | 2022-08-04 | Regenxbio Inc. | Gene therapy for neuronal ceroid lipofuscinoses |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4394448A (en) | 1978-02-24 | 1983-07-19 | Szoka Jr Francis C | Method of inserting DNA into living cells |
US4241046A (en) | 1978-11-30 | 1980-12-23 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
US5036006A (en) | 1984-11-13 | 1991-07-30 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
US4945050A (en) | 1984-11-13 | 1990-07-31 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
DE69032284T2 (de) | 1989-03-21 | 1998-10-08 | Vical, Inc., San Diego, Calif. | Expression von exogenen polynukleotidsequenzen in wirbeltieren |
US5676954A (en) | 1989-11-03 | 1997-10-14 | Vanderbilt University | Method of in vivo delivery of functioning foreign genes |
US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
US5955088A (en) | 1992-02-03 | 1999-09-21 | Cedars-Sinai Medical Center | Pharmaceutical compsition of herpes simplex virus type-1 (HSV-1), glycoproteins |
DK0584348T3 (da) | 1992-03-11 | 2005-09-19 | Powderject Vaccines Inc | Genetisk vaccine mod immundefektvirusser |
US5593972A (en) | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
AU7019494A (en) * | 1993-05-20 | 1994-12-20 | Baylor College Of Medicine | Genetic therapy for cardiovascular disease |
US5614503A (en) | 1993-11-12 | 1997-03-25 | Aronex Pharmaceuticals, Inc. | Amphipathic nucleic acid transporter |
US5739118A (en) | 1994-04-01 | 1998-04-14 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
AU2656295A (en) * | 1994-06-02 | 1996-01-04 | Chiron Corporation | Nucleic acid immunization using a virus-based infection/transfection system |
US5837533A (en) | 1994-09-28 | 1998-11-17 | American Home Products Corporation | Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent |
IT1270123B (it) * | 1994-10-05 | 1997-04-28 | Dompe Spa | Composizioni farmaceutiche contenenti microorganismi ingegnerizzati e loro uso per terapia |
US5707618A (en) | 1995-03-24 | 1998-01-13 | Genzyme Corporation | Adenovirus vectors for gene therapy |
US5756283A (en) | 1995-06-05 | 1998-05-26 | The Trustees Of The University Of Pennsylvania | Method for improved production of recombinant adeno-associated viruses for gene therapy |
AU734443C (en) | 1996-10-23 | 2005-04-14 | Wyeth | Vaccines |
JP2002504380A (ja) * | 1998-02-27 | 2002-02-12 | ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルベニア | ワクチン、免疫療法剤およびそれらの使用法 |
-
2001
- 2001-07-27 AT AT01963746T patent/ATE381351T1/de not_active IP Right Cessation
- 2001-07-27 WO PCT/US2001/023648 patent/WO2002010410A1/en active IP Right Grant
- 2001-07-27 CA CA002417364A patent/CA2417364A1/en not_active Abandoned
- 2001-07-27 JP JP2002516326A patent/JP2004505113A/ja not_active Abandoned
- 2001-07-27 DE DE60131975T patent/DE60131975T2/de not_active Expired - Fee Related
- 2001-07-27 US US10/333,802 patent/US7569218B2/en not_active Expired - Lifetime
- 2001-07-27 EP EP01963746A patent/EP1305435B1/de not_active Expired - Lifetime
- 2001-07-27 AU AU8467201A patent/AU8467201A/xx active Pending
- 2001-07-27 AU AU2001284672A patent/AU2001284672B2/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
AU8467201A (en) | 2002-02-13 |
US7569218B2 (en) | 2009-08-04 |
DE60131975D1 (de) | 2008-01-31 |
WO2002010410A1 (en) | 2002-02-07 |
EP1305435A4 (de) | 2004-06-16 |
EP1305435A1 (de) | 2003-05-02 |
DE60131975T2 (de) | 2008-12-18 |
US20040014705A1 (en) | 2004-01-22 |
AU2001284672B2 (en) | 2007-05-24 |
CA2417364A1 (en) | 2002-02-07 |
JP2004505113A (ja) | 2004-02-19 |
EP1305435B1 (de) | 2007-12-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1044798A1 (en) | Her-2/neu fusion proteins. | |
WO2002012341A3 (en) | Her-2/neu fusion proteins | |
DK0835133T3 (da) | Rekombinant koppevirus-rabies-præparater og kombinationspræparater samt anvendelser deraf | |
GEP19981289B (en) | Method for Preparing Preserved Medicinal Means Containing Human Protein and Medicinal Means | |
DK0561890T3 (da) | DNA ekspressionssystemer baseret på alphavira | |
PT1090033E (pt) | Particulas de proteinas de envelope do hcv: utilizacao para vacinacao | |
WO2002006316A3 (en) | Alpha-msh related compounds and methods of use | |
DE69939327D1 (de) | Funktionelle antagonisten von hedgehog-aktivität | |
IL220133A0 (en) | Nucleic acid molecules and recombinant vaccines comprising sequences encoding immunogens and immunomodulators, compositions comprising said nucleic acid molecules, and uses of said nucleic acid molecules, recombinant vaccines, compositions and immunogens and immunomodulators in the preparation of medicaments and as medicaments | |
FI953378A (fi) | Sytokiiniä pidättävät aineet | |
ATE91630T1 (de) | Pharmazeutische zusammensetzung zur verhuetung oder heilung von durch den papillomavirus induzierten tumoren. | |
MXPA02006888A (es) | Flavivirus recombinantes y metodos para utilizar los mismos. | |
MY150893A (en) | Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines | |
ATE381351T1 (de) | Anwendung des herpes simplex virus glykoproteins- d zur unterdrückung von immunantworten | |
WO2003048205A3 (fr) | Proteines a activite inhibitrice de l'il-6 | |
EP1613345A4 (de) | Zusammensetzungen und verfahren mit dem respiratory syncytial virus untergruppe b stamm 9320 | |
ATE319833T1 (de) | Impfstoffe zur erhöhung der immunantworten gegen herpes simplex virus | |
EP1037918A4 (de) | Verfahren und zusammensetzungen zur steigerung der effizienz von impfstoffen unter verwendung von chemokinen | |
WO2005011571A3 (en) | Hepatitis virus core proteins as vaccine platforms and methods of use thereof | |
ATE272713T1 (de) | Ehv-1 vektoren | |
WO2001040313A3 (en) | Feline immunoregulatory proteins, nucleic acid molecules, and uses thereof | |
WO2001058477A3 (de) | Immunisierung eines individuums gegen carcinome und ihre vorstufen | |
DE50212580D1 (de) | Rekombinantes mva mit der fähigkeit zur expression von hcv struktur-antigenen | |
WO2001049712A3 (en) | Vaccine against isav (infectious salmon anaemia virus) | |
DE60024977D1 (de) | Klonierung und expression von haemophilus somnus transferrin-bindenden proteinen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |